Clinical Trials
14 trialsNCT04305444 2025-01-08
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
Phase 2 Terminated
NCT01854606 2020-12-19
COEB071X2103
Novartis
Phase 1 Completed
NCT01075321 2020-10-22
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT00918333 2020-03-10
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT00436618 2019-10-22
Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Mayo Clinic
Phase 2 Completed
NCT00474929 2019-08-20
Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Mayo Clinic
Phase 1/2 Completed
NCT02240719 2019-01-04
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
University of California, Davis
Phase 1 Completed
NCT01334502 2017-08-10
Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 1 Completed
NCT00790036 2017-07-12
PILLAR2
Novartis
Phase 3 Completed
NCT00978432 2016-11-25
Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Duke University
Phase 2 Terminated
NCT00671112 2015-10-28
Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT00352443 2015-03-06
S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 1 Completed
NCT00869999 2014-10-27
Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Massachusetts General Hospital
Phase 2 Completed
NCT00962507 2013-02-15
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
City of Hope Medical Center
Phase 1 Completed